InvestorsHub Logo
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Tuesday, 04/11/2017 10:11:07 AM

Tuesday, April 11, 2017 10:11:07 AM

Post# of 23979
AXSM (MC $90M)(Cash $50M) 5x Phase3 Programms , get some of this terrible undervalued and unknown gem guys .

Marketcap: $90 Million
Cash: $50 Million
Price: $3.95

New Presentation
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3


AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.